INVITATION
AstraZeneca - Improving outcomes with immuno-oncology: Evolving treatment paradigms for first-line ES-SCLC and unresectable stage III NSCLC
INVITATION
MSD -Extending Longer-Term survival in Lung Cancer and HNSCC with IO and Novel Combinations
INVITATION
AstraZeneca - Emerging immuno-oncology combinations for the treatment of HCC